Abstracts Archive - Page 1174 of 2425 - ACR Meeting Abstracts

Abstract Number: 2543 • 2018 ACR/ARHP Annual Meeting
Retention Rate and Safety Data of Biosimilar CT-P13 in Patients with Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
Hyoun-Ah Kim¹, Eun-Young Lee², Sun Kyung Lee³, Yong-Beom Park⁴, Young Nam Lee⁵, HeeJung Kang⁶ and Kichul Shin⁷, ¹Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South), ²Department of Medical Informatics, Ajou University School of Medicine, Suwon, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), ⁴Yonsei University College of Medicine, Seoul, Korea, Republic of (South), ⁵Celltrion Healthcare Co. Ltd, Incheon, Korea, Republic of (South), ⁶Celltrion Healthcare Co.Ltd, Incheon, Korea, Republic of (South), ⁷Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South)
Background/Purpose: CT-P13 is a biosimilar prescribed in a number of countries for indications approved for the reference infliximab (RINF) including rheumatoid arthritis (RA), ankylosing spondylitis…
Abstract Number: 2544 • 2018 ACR/ARHP Annual Meeting
Changes of CD4-(CD8+) Regulatory T Cells in Rheumatoid Arthritis Patients and during Interleukin-2 Therapy
Xiaoxia Jia¹, Fang Li², Jing Luo³, Chong Gao⁴ and Xiao-Feng Li¹, ¹Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China, ²Department of Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China, ³the Second Hospital of Shanxi Medical University, Taiyuan, China, ⁴Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA
Background/Purpose: Recent studies have showed that quantitative and/or functional abnormalities of the regulatory T cells (Tregs) may play a vital role in the development of…
Abstract Number: 2545 • 2018 ACR/ARHP Annual Meeting
Use of Oral Complementary Medicine in Inflammatory Arthritis: Data from the Australian Rheumatology Association Database (ARAD)
Ashley Fletcher^1,2, Margaret P. Staples^3,4, Catherine Hill^5,6,7, Marissa Lassere⁸, Lyn March^9,10,11,12, Graeme Carroll¹³, Claire Barrett¹⁴, Vibhasha Chand⁴ and Rachelle Buchbinder^4,15, ¹Monash Department of Clinical Epidemiology, Cabrini Institute, Melbourne, Australia, ²Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia, ³Monash Department of Clinical Epidemiology, Cabrini Institute, Malvern, Australia, ⁴Monash University, Melbourne, Australia, ⁵The Queen Elizabeth Hospital, Adelaide, Australia, ⁶Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁷Medicine, The University of Adelaide, Adelaide, Australia, ⁸University of New South Wales, Sydney, Australia, ⁹Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ¹⁰Institute of Bone and Joint Research, University of Sydney, Sydney, Australia, ¹¹Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ¹²Rheumatology, University of Sydney, Insitute of Bone and Joint Research, Royal North Shore Hospital, St Leonards NSW, Australia, ¹³Adult Rheumatology and Osteoarthritis, University of Notre Dame, Mount Lawley WA, Australia, ¹⁴Redcliffe Hospital, University of Queensland, Redcliffe, Australia, ¹⁵Cabrini Institute, Victoria, Australia
Background/Purpose: To describe the use of oral complementary medicine (CM) in people with inflammatory arthritis. Methods: The Australian Rheumatology Association Database (ARAD), an observational database,…
Abstract Number: 2546 • 2018 ACR/ARHP Annual Meeting
The Association between Patient Reported Outcomes and Clinical Measures Among Rheumatoid Arthritis Patients: Analyses Using Phase 3 Clinical Trials of Upadacitinib
Vibeke Strand¹, Nemanja Damjanov², Craig Scoville³, Namita Tundia⁴, Heidi S. Camp⁴, Kun Chen⁴, Jessica Suboticki⁴ and Ronald van Vollenhoven⁵, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, ³Idaho Falls Arthritis Clinic, Idaho Falls, ID, ⁴AbbVie Inc., North Chicago, IL, ⁵Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands
Background/Purpose: Patient-reported outcomes (PROs) in RA are important to evaluate total disease impact, although treatment decisions may often be guided by traditional physician-derived measures of…
Abstract Number: 2547 • 2018 ACR/ARHP Annual Meeting
Upadacitinib Monotherapy Improves Patient-Reported Outcomes in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate
Vibeke Strand¹, Maya Buch², Namita Tundia³, Heidi S. Camp³, Jessica Suboticki³, Debbie Goldschmidt⁴ and Alvin F. Wells⁵, ¹Stanford University, Palo Alto, CA, ²NIHR Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³AbbVie Inc., North Chicago, IL, ⁴Analysis Group Inc., New York, NY, ⁵Rheumatology and Immunotherapy Center, Franklin, WI
Background/Purpose: Upadacitinib (UPA) is a selective JAK-1 inhibitor with demonstrated patient-reported benefits in the treatment of active rheumatoid arthritis (RA).1,2 The objective of this analysis…
Abstract Number: 2548 • 2018 ACR/ARHP Annual Meeting
The Impact of Rheumatoid Arthritis on Patient-Reported Outcomes: Comparison between Sarilumab Clinical Trials and Real-World Patient Data
Vibeke Strand¹, Colleen M. Carpinella², Lulu K. Lee², Susan Boklage³ and Matthew Reaney⁴, ¹Stanford University School of Medicine, Palo Alto, CA, ²Kantar Health, San Mateo, CA, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Sanofi, Guildford, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) and its treatment have significant impacts on health-related quality of life (HRQoL), work productivity (WP) and activity participation. Data are limited…
Abstract Number: 2549 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Benefits of Sarilumab Monotherapy in Adult Patients with Active Rheumatoid Arthritis: Results from an Open-Label Extension Study
Vibeke Strand¹, Matthew Reaney², Erin Mangan³, Hubert van Hoogstraten⁴, Susan Boklage³ and Chih-Chi Hu⁵, ¹Stanford University School of Medicine, Palo Alto, CA, ²Sanofi, Guildford, United Kingdom, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Sanofi Genzyme, Bridgewater, NJ, ⁵Sanofi, Bridgewater, NJ
Background/Purpose: Sarilumab is a human monoclonal antibody that binds to membrane and soluble IL-6R, which is approved for the treatment of moderate to severe rheumatoid…
Abstract Number: 2550 • 2018 ACR/ARHP Annual Meeting
Phase 3 Equira 48 Week Study Results Demonstrated No Impact on Efficacy and Safety When Patients with Moderate-to-Severe Rheumatoid Arthritis Were Switched between Reference Etanercept (ETN) and GP2015, an Etanercept Biosimilar
Arthur Kavanaugh¹, Marco Matucci-Cerinic², Hendrik Schulze-Koops³, Maya Buch⁴, Yannick Allanore⁵, Eugeniusz J. Kucharz⁶ and Goran Babic⁷, ¹UC San Diego School of Medicine, La Jolla, California, La Jolla, CA, ²Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ³Ludwig-Maximilians-University, Munich, Germany, Munich, Germany, ⁴University of Leeds, United Kingdom, Leeds, United Kingdom, ⁵Cochin Hospital, Paris Descartes University, Paris, France, Paris, France, ⁶Department of Internal Medicine and Rheumatology, Medical University of Silesia, Katowice, Poland, Katowice, Poland, ⁷Hexal AG, a Sandoz company, Holzkirchen, Germany, Holzkirchen, Germany
Background/Purpose: Compared to ETN, GP2015 has equivalent efficacy, and comparable safety and immunogenicity in patients with chronic plaque-type psoriasis.1 The purpose of this study is…
Abstract Number: 2551 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Treatment with Filgotinib: Week 132 Safety Data from a Phase 2b Open-Label Extension Study
Arthur Kavanaugh¹, Mark C. Genovese², Kevin Winthrop³, Maria Greenwald⁴, Lucia Ponce⁵, Favio Enriquez Sosa⁶, Mykola Stanislavchuk⁷, Minodora Mazur⁸, Alberto Spindler⁹, Regina Cseuz¹⁰, Natalya Nikulenkova¹¹, Maria Glowacka-Kulesz¹², Istvan Szombati¹³, Anna Dudek¹⁴, Neelufar Mozaffarian¹⁵, Joy Greer¹⁶, Rebecca Kunder¹⁵, Di An¹⁷, Luc Meuleners¹⁸, Robin Besuyen¹⁸, Rieke Alten¹⁹ and René Westhovens²⁰, ¹University of California, San Diego, School of Medicine, La Jolla, CA, ²Stanford University Medical Center, Palo Alto, CA, ³Oregon Health and Science University, Portland, OR, ⁴Desert Medical Advances, Palm Desert, CA, ⁵Cons. Priv. Temuco, Temuco, Chile, ⁶Clinstile SA de CV, Col., Mexico City, Mexico, ⁷Rheumatology, Vinnytsia Regional Clinical Hospital, Vinnytsia, Ukraine, ⁸IMSP Inst. de Cardiologie, Chisinau, Moldova, The Republic of, ⁹Centro Médico Privado de Reumatología, Centro Médico Privado de Reumatología, Argentina, ¹⁰Revita Reumatologiai Kft, Budapest, Hungary, ¹¹Vladimir Reg Clin Hosp, Vladimir, Russian Federation, ¹²Silesiana Centrum Medyczne, Wroclawska, Poland, ¹³Qualiclinic Kft., Budapest, Hungary, ¹⁴AMED Medical Center, Warsaw, Poland, ¹⁵Gilead Sciences, Inc., Foster City, CA, ¹⁶Gilead Sciences, Inc, Foster City, CA, ¹⁷Gilead Science, Inc., Foster City, CA, ¹⁸Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, ¹⁹Schlosspark-Klinik University Medicine, Berlin, Germany, ²⁰Rheumatology, University Hospital KU Leuven, Leuven, Belgium
Background/Purpose: The orally administered, selective inhibitor of Janus Kinase 1 (JAK1), filgotinib (FIL), is currently being investigated for the treatment of rheumatoid arthritis (RA) in…
Abstract Number: 2552 • 2018 ACR/ARHP Annual Meeting
Fatigue in Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Early Improvement Is Associated with Week 24 Outcomes in Acr 20, 50, and Health-Related Quality of Life
Arthur Kavanaugh¹, M. Elaine Husni², Eric K. H. Chan³, Diane D. Harrison⁴, Lilianne Kim⁴, Kim Hung Lo⁴, Elizabeth C Hsia⁵ and Chenglong Han⁶, ¹University of California, San Diego, School of Medicine, La Jolla, CA, ²Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ³Janssen Global Services, LLC, Raritan, NJ, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁶Janssen Global Services, LLC, Malvern, PA
Background/Purpose: To investigate improvement in fatigue in adult patients with active psoriatic arthritis (PsA) treated with intravenously administered (IV) golimumab, an anti-TNFα…
Abstract Number: 2553 • 2018 ACR/ARHP Annual Meeting
Secukinumab Provides Early and Sustained Improvements in Health-Related Quality of Life in Patients with Psoriatic Arthritis: Pooled Results from the Secukinumab Phase 3 Trial Program
Vibeke Strand¹, Oliver FitzGerald², Laura C. Coates³, Jessica Walsh⁴, Juan D. Cañete⁵, Peter Nash⁶, Eric Davenport⁷, Luminita Pricop⁸, Gregory Hustache⁹, Nicolas Scheuer⁹, Isabelle Gilloteau⁹ and Matthias Augustin¹⁰, ¹Stanford University, Palo Alto, CA, USA, Palo Alto, CA, ²St Vincent's University Hospital and Conway Institute, University College Dublin, Ireland, Dublin, Ireland, ³University of Oxford, Oxford, UK, Oxford, United Kingdom, ⁴University of Utah School of Medicine, Salt Lake City, UT, USA, Salt Lake City, UT, ⁵Rheumatology Deparment, Hospital Clinic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ⁶University of Queensland, Brisbane, Queensland, Australia, St Lucia, Brisbane, Australia, ⁷RTI Health Solutions, Research Triangle Park, NC, USA, Research Triangle Park, NC, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ¹⁰University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Hamburg, Germany
Background/Purpose: Improving health-related quality of life (HRQoL) is a key goal of psoriatic arthritis (PsA) therapy. Secukinumab, a fully-human IL-17A inhibitor, has been shown to…
Abstract Number: 2554 • 2018 ACR/ARHP Annual Meeting
Abatacept without Methotrexate in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of a Phase III, Randomized Study
Vibeke Strand¹, Thomas Lehman², Harris A Ahmad², Alyssa Johnsen², Sandhya Balachandar² and Philip J. Mease³, ¹Stanford University, Palo Alto, CA, ²Bristol-Myers Squibb, Princeton, NJ, ³Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: In the randomized, placebo (pbo)-controlled Phase III ASTRAEA study (ClinicalTrials.gov, NCT01860976) patients (pts) with active psoriatic arthritis (PsA) were randomized to abatacept (ABA) or…
Abstract Number: 2555 • 2018 ACR/ARHP Annual Meeting
Ixekizumab Treatment Results in Rapid and Sustained Improvements in the Disease Activity Index for Psoriatic Arthritis (DAPSA) in Patients Naïve to Biologic Dmards or with Previous Inadequate Response to TNF Inhibitors
Prashanth Sunkureddi¹, Baojin Zhu^2,3, Alexis Ogdie⁴, Aubrey Spraberry³, Jeffrey Lisse³, Chen-Yen Lin³ and David Shrom², ¹Rheumatology, Clear Lake Rheumatology Center, Nassau Bay, TX, ²LRL, Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: The DAPSA is a composite tool that assesses several domains of psoriatic arthritis (PsA) manifestations and was developed as a disease activity measure for…
Abstract Number: 2556 • 2018 ACR/ARHP Annual Meeting
Secukinumab 150mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis with Consistent Safety Profile and High Retention Rate: 4-Year Results from a Phase III Trial
Helena Marzo-Ortega¹, Joachim Sieper², Alan J. Kivitz³, Ricardo Blanco⁴, Martin Cohen⁵, Evie Maria Delicha⁶, Susanne Rohrer⁶ and Hanno Richards⁶, ¹NIHR LBRC, LTHT and LIRMM, University of Leeds, Leeds, United Kingdom, ²University Clinic Benjamin Franklin, Berlin, Germany, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵McGill University, Montreal, QC, Canada, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human monoclonal IgG1 antibody that neutralizes IL-17A, has shown significant and sustained improvement in the signs and symptoms of active ankylosing…
Abstract Number: 2557 • 2018 ACR/ARHP Annual Meeting
Efficacy of Ustekinumab on Spondylitis-Associated Endpoints in TNF-Naïve Active Psoriatic Arthritis Patients with Physician-Reported Spondylitis
Philip Helliwell¹, Dafna D Gladman², Soumya D Chakravarty³, Shelly Kafka⁴, Chetan S Karyekar⁴, Yin You⁵, Arthur Kavanaugh⁶ and Lianne S. Gensler⁷, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK, Leeds, United Kingdom, ²Department of Medicine, Toronto Psoriatic Arthritis Research Program, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Janssen Scientific Affairs, LLC/Drexel University School of Medicine, Horsham/Phila, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶University of California, San Diego, School of Medicine, La Jolla, CA, ⁷University of California San Francisco, San Francisco, CA
Background/Purpose: In PSUMMIT 1&2, Phase 3 trials of ustekinumab (UST) in adults w/ active psoriatic arthritis (PsA), 30.1% & 22.4% of patients (pts) had peripheral…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].